Читать книгу Transfusion Medicine - Jeffrey McCullough - Страница 150

A virally inactivated fibrinogen concentrate prepared from human plasma is now available commercially and is approved by the FDA for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency [108–110]. The concentrate is recommended for use in situations when the fibrinogen level is less than 100 mg/dL. Although fibrinogen concentrate is approved only for use in congenital fibrin deficiency [109], small studies of its use in patients with low fibrinogen levels and massive bleeding from obstetric complications, cardiovascular surgery, intra‐abdominal surgery, trauma [108], and an aortic ascending aorta replacement [110] have demonstrated substantially reduced bleeding, and these situations have become its major use [111].